Nektar Therapeutics Reports Second Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Needham Starts NeoVolta (NEOV) at Buy
- Earthquakes shake Venezuela capital
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Nektar Therapeutics (NKTR) Tops Q2 EPS by 9c
August 4, 2022 5:18 PM EDTNektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($0.85), $0.09 better than the analyst estimate of ($0.94). Revenue for the quarter came in at $21.6 million versus the consensus estimate of $22.75 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
... More